ClinicalTrials.gg
WithdrawnNCT04086342Updated Jun 4, 2020

CHI-902 for Treatment of Social Anxiety Disorder

A Phase 2 interventional study of CHI-902 and Placebo in Social Anxiety Disorder, sponsored by Canopy Growth Corporation. Withdrawn at 2 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Canopy Growth Corporation · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Changes in pipeline

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Phobia, Social with a site in Canada — none open to participants now, 2 under way, none of them phase 3. Phobia, Social · Canada.

Enrollment
28th of 29
0 · median 60
Started
2020
the only one that year
Phase 2
6 of 29
none open now
Registered
24th of 29
by date
Lead sponsor
1 of 29
Canopy Growth Corporation

Among the 29 studies in Phobia, Social with a site in Canada, this one is the 28th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 2, and was the 24th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

None of the 29 studies in Phobia, Social with a site in Canada is open now. The open studies under Phobia, Social, anywhere →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Phobia, Social with a site in Canada as a file.
02

Study summary

No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA) and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.

Read the detailed description

This study will evaluate efficacy, therapeutic effects, tolerability and safety of CBD oil in adults with SAD through a randomized placebo-controlled study design and will evaluate effects of CHI-902 on peripheral endocannabinoids (AEA and 2-AG). This study will be the first randomized, double-blind placebo-controlled trial conducted with CHI-902 in adults with SAD.

The study is designed to:

  • Evaluate the efficacy of CHI-902 versus placebo in adults with SAD.
  • Evaluate the tolerability and safety versus placebo of CHI-902 in adults with SAD.
  • Explore the effects of CHI-902 versus placebo on different biomarkers in subjects with SAD.
03

Conditions studied

  • Social Anxiety Disorder

Keywords

  • Anxiety
  • Cannabis
  • Cannabidiol
  • CBD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: Adult males or females (≥18 years of age) will be enrolled until the required number of n=160 subjects completing all study procedures is met. Individuals will be included if they:

  1. Meet criteria for SAD
  2. Score >60 on the Liebowitz Social Anxiety Scale (LSAS)

Exclusion Criteria:

  1. Serious, unstable medical condition including but not limited to cerebrovascular, renal, hepatic, coronary heart disease, coagulation/blood disorders, use of anticoagulant medication, pre-existing cardiovascular disease including poorly controlled hypertension, ischaemic heart disease, arrhythmia, or heart failure;
  2. Past or current neurological illness or head trauma;
  3. History of bipolar disorder, psychotic disorder/schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, or personality disorder (Cluster A or B);
  4. Current moderate or severe major depressive episode, panic disorder, generalized anxiety disorder, or post-traumatic stress disorder (PTSD). Traits associated with these disorders are permissible but full DSM criteria should not be met;
  5. Current psychotic symptoms;
  6. Current suicidal ideation or suicide attempt or self-harm behavior in the past year;
  7. Current unstable psychiatric condition;
  8. Substance use disorder in the past 6 months except nicotine
  9. Cannabis use or use of medications or drugs targeting endocannabinoid system including but not limited to nabiximols, nabilone, or synthetic cannabinoids in the past 3 months;
  10. Regular pharmacological treatment with psychotropic medications except benzodiazepines which may be used as a rescue medication
  11. Pharmacological treatment with medications with potential significant drug-drug interactions with CBD through Cytochrome P450 metabolization (, CYP2C9, CYP2C19, CYP1A1) based on the Investigator assessment;
  12. Pregnancy or lactation;
  13. Males and females of must be using and willing to continue using medically acceptable throughout the study to avoid pregnancy during the study and for up to 4 weeks after study completion, as described below. Study-acceptable methods of birth control are double-barrier methods, which include a combination of any 2 of the following: oral contraceptives, diaphragm, condom, copper intrauterine device, sponge, spermicide, or (partner's) vasectomy;
  14. Positive urine during drug screening for drugs of abuse (except benzodiazepines);
  15. Reported history of difficulty with intravenous blood draws;
  16. Allergy to or intolerability of cannabinoids, CBD or other ingredients of the product;
  17. Baseline liver, renal, or hematological laboratory abnormalities.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    CHI-902

    Study subjects will enter a titration phase of 1 week with a daily oral CBD dose of 150 mg (50 mg three times daily). Then, daily CBD dose of 300 mg or matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).

    Drug: CHI-902

  • Placebo comparator
    Placebo

    Study subjects will enter a titration phase of 1 week with a daily oral dose of 150 mg (50 mg three times daily) of matching placebo. Then, daily dose of 300 mg of matching placebo will be given for 3 weeks (treatment phase 1; fixed dose).

    Drug: Placebo

Interventions

  • A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.

    Also known as: CBD Oil

  • DrugPlacebo

    Placebo is a vehicle oil that will match CHI-902.

    Also known as: Placebo Oil

06

What researchers measure

Primary outcomes

  1. Liebowitz Social Anxiety Scale (LSAS)

    Quantitative change in LSAS total score from baseline to endpoint (week 10) in subjects receiving active treatment with CHI-902 compared to subjects receiving placebo. The scale is composed of 24 items divided into 2 subscales, 13 concerning performance anxiety, and 11 pertaining to social situations. The 24 items are first rated on a scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points. Research supports a cut-off point of 30, in which SAD is unlikely. The next cut-off point is at 60, at which SAD is probable. Scores between 60 and 90 indicate that SAD is very probable. Scores higher than 90 indicate that SAD is highly probable.

    Time frame: Baseline to endpoint (week 10)

Secondary outcomes

  1. Systematic Assessment of Side Effects in Clinical Trials (SAFTEE)

    Safety and adverse effects with the Systematic Assessment for Treatment Emergent Events (SAFTEE). Tolerability of treatment assessed by SAFTEE in subjects receiving active treatment with CHI-902 compared to subjects receiving placebo, and safety through number of subjects dropping out due to SAEs in the two groups.

    Time frame: After 10 weeks of treatment.

07

Study locations

2 sites
  • MacAnxiety Research Center, McMaster University
    Hamilton, Ontario L8S 1B8, Canada
  • Centre for Addiction and Mental Health (CAMH)
    Toronto, Ontario, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2020; primary completion for Jan 2021, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Sep 11, 2019
StartEst.
Jan 24, 2020
Primary completionEst.
Jan 26, 2021
CompletionEst.
Jan 26, 2021
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04086342
Lead sponsor
Canopy Growth Corporation
Responsible party
Sponsor
First posted
Sep 11, 2019
Start date
Jan 24, 2020 (estimated)
Primary completion
Jan 26, 2021 (estimated)
Completion
Jan 26, 2021 (estimated)
Last update
Jun 4, 2020

Study contacts

Mark Ware, MD
study director · Canopy Growth Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion